Exploring the next generation of antibody–drug conjugates

Tumour heterogeneity and resistance to cancer therapies

Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846

PROTAC targeted protein degraders: the past is prologue

Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395

Strategies and challenges for the next generation of antibody–drug conjugates

Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917

Prodrugs: design and clinical applications

Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D.-M., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,681

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

Junutula, J. R., Raab, H. E., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,388

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,228

Unlocking the potential of antibody–drug conjugates for cancer therapy

Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,209

Therapeutic Applications and Target Strategies of Antibody-Drug Conjugates in Ovarian Cancer

Liu, Q., Zhou, R., He, T., Zhao, Y., & Yang, M. (2025) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-165383

Engineering the Future of Cancer Care: How Next-Generation Antibody-Drug Conjugates (ADCs) Are Shaping Oncology and Beyond

AbbVie, & Eleni Lagkadinou, M. (2025) · ADC Review / Journal of Antibody-drug Conjugates · doi:10.14229/jadc.2025.10.08.001

Current landscape of cross-line immune checkpoint blockade for cancer treatment

Fan, P., Wu, K., Zhu, C., & Guan, X. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218135

Oncofetal chondroitin sulfate in cancer therapy: a promising target for anti-tumor drug delivery?

Vidal-Calvo, E. E., & Salanti, A. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2606747

New insights into therapeutic strategies against Zika virus from virus–host interactions

Li, Q., Dong, Y., Chen, Z., Zhang, H., Wang, Z., Liu, N., Lu, M., Zhu, W., Xing, H., & Zheng, A. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102902

Blood compatibility of silk nanoparticles: impact of size and dose

Maitz, M. F., Totten, J. D., Weiss, A. C. G., Besford, Q. A., Werner, C., & Seib, F. P. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126526

Quantum weak measurement biosensor for label-free drug-to-antibody ratio determination of T-DXd

Wang, S., Liu, Y., Zhou, Y., Chen, Y., Yao, J., Zhang, J., Li, D., Lin, Q., & Ruan, Y. (2026) · Optics Express · doi:10.1364/oe.583299

Combining a homogenous KIM-1-DM1 antibody drug conjugate with sunitinib in renal cell carcinomaPreprint

Thurakkal, L., Velayutham, K., Sarkar, B., Kalyan, A., Jang, H. L., Sengupta, S., & Saha, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.12.699160

A prostate-specific membrane antigen targeted small molecule-drug conjugate for efficient prostate cancer therapy at a low dosage

Zhang, J., Hu, F., Deng, C., Ding, Y., Yang, Y., Han, S., Liu, J., An, F., & Shi, M. (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100496

Enhanced Payload Release Enables Disitamab Vedotin to Surpass Trastuzumab Emtansine and Retain Efficacy in Acquired Resistance to Clinical Anti-HER2 Therapies

Redondo-Puente, M., Gómez-García, M. D. C., & Pandiella, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18020208

An Integrated NMR Approach for Evaluating Linker-Payload Conjugation with Monoclonal Antibodies

Ghini, V., Siciliano, S., Querci, L., Angiolini, L., Truglio, G. I., Cini, E., Piccioli, M., Petricci, E., & Turano, P. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00017

Antibody Drug Conjugates

Hays, P. V. (2026) · Springer eBooks · doi:10.1007/978-3-032-14437-9_8

Targeting EMP2 with a Granzyme B Fusion Protein Modulates Immune Infiltration and Inhibits Breast Tumor Progression

Muhammad, A. B., & Abdullah, F. B. (2023) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/b5il1ouno9

Therapeutic targeting of toll-like receptor pathways in tumor-associated macrophages

Wang, L., Li, Y., He, Z., Chen, Z., Zhang, W., Wu, C., Xue, L., & Cao, X. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.02.001 · Cited by 1

Multibody-Enabled Lysosome-Targeting Drug Conjugates for Target Protein Degradation and Combination TherapyPreprint

Zhang, L., Chen, L., Yao, S., Tian, X., ping, L., Tan, P., Sun, Q., Gu, Y., Wen, Y., Huang, J., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8651044/v1

Development of a HER1/CP2c dual-targeting biopharmaceutical for HER1-overexpressing head and neck cancer

Byun, K. T., Cho, J., Kim, B., Lee, I., Kim, E. B., Park, D., Han, S.-W., Hyung-Sik, W., Cheon, S. Y., & Kim, C. G. (2026) · Biomaterials Advances · doi:10.1016/j.bioadv.2026.214782

Antibody–Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next‐Generation Strategies Against Multidrug‐Resistant Bacterial Infections

Askari, P., Eshaghi, S., Omidvar, L., & Mahi‐Birjand, M. (2026) · MicrobiologyOpen · doi:10.1002/mbo3.70234 · Cited by 1

Modification Glycoside on IgG: Preparation of IgG with Homogeneous Glycan and Expansion to Antibody–Drug Conjugate

Manabe, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-5335-8_12

DVD-IgG1 antibody–drug conjugates: Expanding the landscape of targeted cancer therapy

Kiefer, A. F., Steele, A. D., Rader, C. M., & Shen, B. (2026) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2026.102653

Advancing Genetic Code Expansion in Live Cells Through Metabolic Engineering

Wyllis, D. R., Gupta, S. P., Anderson, S. R., & Kunjapur, A. M. (2026) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-100724-081506

Comparative Analysis of Methods for the Formation and Cytostatic Activity of the Vesicular Form of Doxorubicin

Плевако, Д. С., Garanin, A., Vasileva, O. A., Yevtushenko, V., Якубович, Е. И., & Malek, A. V. (2025) · Nanobiotechnology Reports · doi:10.1134/s2635167625600518

Layers of Hope: How Graphene and Nanostructures Hold Promise for Cancer Therapy

Ribeiro, B. F. M., & Machado‐Santelli, G. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052336

Design of potent, proteolytically stable stapled lipopeptide analogues of BimBH3 as PTP1B inhibitors for diabetes therapy

Gu, Z., Gao, X., Wu, H., Yan, Z., Feng, S., Wang, Y., Shi, Y., Dong, G., Gong, L., Yao, W., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118775

Biocoating of bioactive compounds with antibody-drug conjugates (ADCs): A narrative review on plant, microbial and marine-based macromolecules for treating gut cancers

Sasikala, S., Sowmiya, A., & Usharani, N. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108248

The potential of antibody–antimicrobial conjugates for combating bacterial infections

Zhang, Y., Zhang, Z., Yu, L., & Li, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36518-8.00019-9

Clinical application and optimization strategies for antibody–drug conjugates in solid tumors

Qu, J., Zhao, X., Zhang, L., Cai, W., -, S. M., Liu, X., Wei, X., & Fei, F. (2026) · Journal of International Medical Research · doi:10.1177/03000605261434386

Application of antibody-drug conjugates in locally advanced or metastatic urothelial carcinoma: mechanisms, treatment-related adverse events, and management strategies

Fan, Y., Wang, G., Xu, S., Ge, H., Li, Y., & Wang, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1771653

Second primary cancers following hematologic malignancies: Epidemiology, pathobiology and clinical management

Pan, Y., Yang, H., Shao, J., Qiang, X., & Wang, Q. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2654318

Cyclic monochalcogen bonds enable improved stability and fine-tuned activation of dimeric prodrug nanoassemblies for potent cancer therapy

Zhang, J., Wang, S., Zhang, Y., Yang, X., Liu, T., Dai, Y., Li, Y., Zuo, S., Li, D., He, Z., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114924

Sacituzumab Govitecan as an Effective Strategy for Sensitizing Chemoresistant HNSCC Cells to Senolytic InterventionPreprint

Luffman, N., Hu, B., Koblinski, J. E., Gewirtz, D. A., & Harada, H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.13.718209

Zinc chloride-catalyzed synthesis of indole-based α-aminophosphonates with potent antimicrobial and anticancer activities: in vitro and in silico evaluation

Aljohani, G. F. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2658837

Recent Advancements in Chemotherapy for Targeted Therapeutic Strategy

Agrawal, N., Dewangan, R., Siddiqui, M. A., Lanjhiyana, S. K., & Jaiswal, M. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814113126010011

Overcoming ADC resistance in advanced colorectal cancer by dual targeting of TROP2 and PERK to suppress Wnt/β-catenin signaling

Liu, J., Li, M., Huang, J., Xia, Y., Jiang, G., Zhang, H., Yang, J., Jiang, M., Liu, Y., Luo, Y., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102769

Combinatorial evolution and breakthroughs in multi-functional antibody therapies: development trends of bispecific/trispecific antibody and antibody-drug conjugate in 2025

Wei, L. I., Ying-Xia, L. I. U., Yun, C. H. E. N., Zhao, R.-C., & Wang, Y. (2026) · Shengming kexue · doi:10.3724/cbls.2026029

TCRVβ-targeting antibody-drug conjugates as a novel strategy to eliminate malignant T cells in T cell cancers

Vadivel, C. K., Nørregaard, K. S., Perlado, A. M., Sorrosal, L. P., Zeng, Z., Yan, L., Namini, M. R. J., Gluud, M., Buus, T. B., Engelholm, L. H., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020282

Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics

Yu, C., Ha, S. Y. Y., An, Z., Tsuchikama, K., & Li, W. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag022 · Cited by 2

Next-Generation CDK Inhibitors in Breast Cancer: Expanding the Therapeutic Landscape beyond CDK4/6 Inhibitors

Wu, J., Lai, Y., & Lu, G. (2026) · Breast Care · doi:10.1159/000551834

Multi-modality strategy for creating innovative drugs

Toda, N. (2026) · Folia Pharmacologica Japonica · doi:10.1254/fpj.25060

Multispecific nanobody degraders co-deplete membrane receptors and enable targeted delivery of diverse payloadsPreprint

Kabir, M., Kim, Y. J. (., Deng, Z., Xiang, Y., Sargunas, P. R., Song, N., Wang, Z., Param, N. J., Jin, C., Sang, Z., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.02.722401

Decoding immunotherapy resistance in multiple myeloma: genetic insights and approaches to counter resistance

Li, H., Xia, Q., Yu, M., Lv, Y., Xiao, J., Guo, X., Dong, K., Zhou, Y., Zhong, L., Wang, T., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3227-0

ImmTAC: A Novel Platform of T-Cell Receptor-Based Soluble Bispecifics

Oestringer, B. P., & Vuidepot, A. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5037-0_4

Targeting cancer-associated cell surface RNAs with oligonucleotide-drug conjugates enables broad antitumor activityPreprint

Luo, C., Cheng, C., Zhao, X., Zhou, J., Jing, Z., Ma, Q., Ye, L., Zhu, K., Zhao, L., Xu, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.08.723688

Antibody-Drug Conjugates in Oncology: Mechanisms, Clinical Progress, and Future Directions

Zhu, Z., Wang, S., Hong, W., Zhong, Q., Wang, W., Wang, N., Bai, M., & Ji, Z. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i2.32

Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer

Li, L., Zhao, Y., Shi, X., Guo, X., Zhang, X., Li, G., Meng, Q., Zhang, M., & Yin, M. (2026) · Cancer Drug Resistance · doi:10.20517/cdr.2026.12

Preclinical characterization and phase I results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors

Ruan, D. Y., Lin, S. Y., Huang, J. J., Li, Y. H., Li, N., Qu, X. J., Du, X. B., Yin, Y. M., Yuan, Z. Y., Shi, Y. X., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.05.003 · Cited by 2

Reflection on “Site-specific PEGylation of proteins by a Staudinger-phosphite reaction”: from protein modification to ADCs in the clinic

Schuppe, K. T., & Hackenberger, C. P. R. (2026) · Chemical Science · doi:10.1039/d6sc90102f

ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer

Provencio, M., Aguiar, D., Antoñanzas, M., Areses, M. C., Azkárate, A., Barba, A., Bernabé, R., Blanco, R., Borregón, M., Campos, B., et al. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2677905

Drug-free biomaterials for immune regulation via targeting macrophages, dendritic cells, and T cells

Gong, X., Li, J., Xu, Z. P., & Zhao, J. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.112997

Orthogonal Chemistry Enables Precision Nanoparticle Cofunctionalization for Tuning Immune Stimulation and Antigen Presentation

Heiler, A. J., McClain, C. A., Lucas, S. N., He, G. Z., Finn, M. G., & Thomas, S. N. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.5c02689

Antibody–drug conjugates: a practical review on clinical management of toxicities

Palma, A. D., Marenco, M., Mancini, S., Palaia, I., Barchiesi, G., Donato, V. D., Perniola, G., Petrella, M. C., Muzii, L., & Tomao, F. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2685304 · Cited by 1

Nature-Inspired Nanoparticle Adiposomes Enable Targeted Delivery of Hydrophobic Drug for Anti-Cancer TreatmentPreprint

Pan, B., Cao, Z., Li, Z., Zhang, G., Zhou, C., Zhi, Z., Zhu, Y., Zhang, Q., Lu, S., Zhang, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.01.729180

MultiADC: Advanced Antibody-Drug Conjugate Activity Prediction Through Multi-scale Feature Fusion

Li, M., Wu, Y., Guo, Z., Guo, P., Hu, S., Shengqing, H., & Lan, X. (2026) · Lecture notes in computer science · doi:10.1007/978-981-92-1462-4_47

Unleashing innovative cross-organ fibrosis therapies by harnessing the omics revolution

Lebeaupin, C., Donahue, K. L., Dower, K., Wynn, T. A., Hart, K. M., & Fabre, T. (2026) · JCI Insight · doi:10.1172/jci.insight.200155

Artificial Intelligence-Driven Antibody-Drug Conjugate Development for Chronic Neuropathic Pain: From Target Discovery to Clinical Translation

Liu, Y., Xie, Q., Zhou, H., Shah, K., & Song, S. (2026) · AI Med · doi:10.71423/aimed.20260606

Genomic landscape and tumor immune microenvironment of osteosarcoma: Bridging mechanistic insights to precision therapeutics

Yang, C., Yu, Y., Wang, Y., Cai, Z., Zhao, Y., Ma, H., Xu, J., Zhu, H., Ren, T., Tang, X., et al. (2026) · Bone Reports · doi:10.1016/j.bonr.2026.101930 · Cited by 1

HER2‐Targeted Antibody–Drug Conjugates–Associated Interstitial Lung Disease: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System Data

Du, D., Zhu, Y., Zheng, H., Xu, S., Li, Y.-K., Zhan, P., Yang, J., & Wang, Y. (2026) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/jcpt/7121390

Progress in immune-modulating biomaterials for complement system regulation

Abudousu, A., Tang, Y., Xiang, L., Wang, Z., Li, Y., Zhao, D., Mutailifu, M., Jiang, Q., Liu, B., & Cui, W. (2026) · Progress in Materials Science · doi:10.1016/j.pmatsci.2026.101765

A Newly Designed Antibody–drug Conjugate Targeting B7-H3 Demonstrates Enhanced Therapeutic Efficacy Across a Spectrum of Cancers

Jing, Q., Zhu, X., Zhao, X., Zhu, J., Wu, Z., Zheng, Q., Wang, J., Yu, F., Nie, L., & Weng, Q. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04076-6

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency

Gauntlett, R., Lodge, J., Watson, J., Yates, J. W. T., Cordy, J. M., Sinfield, H., Caruana, R., & Rattray, Z. (2026) · mAbs · doi:10.1080/19420862.2026.2689777

Normalized internalization predicts potency of carcinoembryonic antigen-related cell adhesion molecule 6-targeting antibody–drug conjugates

Lim, J.-Y., Hong, J., Lee, S. H., Lee, S.-G., Chae, B.-H., Son, G.-H., Park, M., Yoo, T. H., Kim, Y., & Lee, C.-H. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115106

Recent advances in glycoconjugate-based therapeutics

Dao, Y., & Dong, S. (2026) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2026.102716

Antibody glyco-optimization and site-specific conjugation enhance the immune-stimulating activity of antibody–TLR ligand conjugates

Wang, Y., Lou, Y., Yun, H., Gomozkova, M., Li, G., Su, L., & Wang, L. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113269

Bifidobacterium infantis-mediated HSV-TK/GCV therapy modulates the tumor microenvironment through site-specific phosphorylation of HIF-1α, mTOR, and PD-L1

He, J., Yuan, Y., Li, J. N., Ma, Y., & 陈地龙 (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1849164

Eficacia y seguridad de los conjugados fármaco-anticuerpo en el tratamiento del cáncer de mama localmente avanzado o metastásico: una revisión sistemática

GUERRA, M. D.-G. D., Valín, A. R. I., Vázquez, L. C., Zas-García, M. I., González, Y. M. T., & Mallo, B. S. (2026) · Ars Pharmaceutica (Internet) · doi:10.30827/ars.v67i3.35793

The emerging roles of alternative splicing in modulating tumor immune responses and immunotherapies

He, X., Zhao, D., Zhou, Y., Jiang, Y., Dong, Z., & Liu, K. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01792-9

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications

Bharath, P., Iyer, S., Velu, A. V., & Kumar, D. T. (2026) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-026-04910-z

Advances and perspectives of next-generation antitumor antibody-based modalities: Structural innovation and target-driven strategies

Sun, L. G., Xu, B., Wang, S., & Li, N. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.028

Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy

Roncato, R., Pasin, D., Dell’Aquila, E., Danesi, R., & Re, M. D. (2026) · Chemotherapy · doi:10.1159/000553142

Site-specific trastuzumab Fab-DM1 via butelase-1 with ABD fusion for potent HER2-positive tumor control

Han, Y., Guo, Q., Cao, H., Qin, T., Zhang, X., Dong, Q., Huang, Y., Mao, Y., Wang, Z., Liu, Q., et al. (2026) · Medical Oncology · doi:10.1007/s12032-026-03317-3

Systemic therapy for HCC: Doublets, triplets and beyond

Vogel, A., & Kelley, R. K. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.04.024

Topological data analysis for antibody-drug conjugate payload discovery: a computational framework for mechanistic classification and target validation

Akgüller, Ö., & Balcı, M. A. (2026) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-026-00877-4

Innovative use of therapeutic antibodies in lung cancer: the current landscape of ADCs and other antibody-based therapies

Lee, M., & Lovly, C. M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1814095

Next generation medicines: Emerging approaches to drug ‘difficult to drug’ targets

Owen, D., Chaparro‐Riggers, J. F., Levengood, M. R., & Tadin‐Strapps, M. (2026) · Disease and Therapeutics · doi:10.1016/j.dist.2026.100016

Emerging mechanisms and targetable pathways in immune checkpoint inhibitor‑associated thyroid dysfunction: From pathogenesis to potential intervention

Zhang, T., Han, H., Shi, H., Ma, M., Zhang, Y., Zhang, T., Ma, L., Yang, Z., & Zhao, Y.-X. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105481

Molecular mechanisms, current therapeutics, and emerging strategies in esophageal cancer: A comprehensive review

Wang, Y., Lian, X., Chen, Y., & Wang, F. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004194

Antibody-drug conjugates for advanced/recurrent high-grade endometrial cancer: potential targets, strategies and challengesPreprint

Matoba, Y., Rodman, E. P. B., Mohammadabadi, M. A., Bouberhan, S., Yeku, O., & Rueda, B. R. (2026) · Research Square · doi:10.21203/rs.3.rs-10205426/v1

Raman Spectroscopy for Characterizing Monoclonal Antibody Reduction: A Process Analytical Technology Approach for Antibody–Drug Conjugation Process Development

Pople, D., Wang, Z., Kozyryev, A., Patel, B. A., Appiah‐Amponsah, E., & Feng, H. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04154-9

Site-specific click chemistry-mediated scaffold engineering to bioorthogonally functionalize cell surface in cell-based therapeutics

Jangid, A. K., Noh, K. M., & Kim, K. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.218312

Linker Chemistry in Antibody–Drug Conjugates: Current Strategies, Clinical Pharmacokinetic Analyses, and Linker-Free Outlooks

Prachyathipsakul, T., Gupta, P., Thayumanavan, S., Vijay, S., Kannan, K., & Thayumanavan, S. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00299

A programmable DNA tetrahedron platform for selective and efficient capture of cells and proteins

Chen, X., Yin, W., Li, S., Cai, X., Lin, Y., & Tian, T. (2026) · Nature Protocols · doi:10.1038/s41596-026-01410-5

Peptide–drug conjugation: a strategy to address blood–brain barrier limitations in central nervous system diseases

Passalacqua, E., Barberi, G., Amico, P., Martino, S. D., & Rosa, M. D. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00420b

Self-assembled nanocomplexes of polyphenol-modified prodrugs and transferrin enable cascade-targeted and redox-activated chemotherapy

Zhang, B., Zhao, Y., Liu, X., Huang, R., Zhou, Y., Ye, J., Li, J., Xu, Z., Cui, W., Yu, J., et al. (2026) · Materials Horizons · doi:10.1039/d6mh00886k

Advances in modified anti-Aβ antibodies for the treatment of Alzheimer’s disease

Li, S., Gu, J., Xu, Z., He, C., & Yu, C. (2026) · BMC Medicine · doi:10.1186/s12916-026-05088-0

Cordycepin-double staple peptide-paclitaxel conjugate enhanced antitumor activity via autophagy and apoptosis pathways

Xie, K., Yang, H., Chen, Z., Li, W., Guo, F., Chen, R., Shao, Q., & Lu, K. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110294

Antibody peptide conjugates as multifunctional therapeutics: Mechanisms, challenges, and prospects

Xie, F., Liu, L., Cheng, Q., Xiao, D., Zhou, X., & Li, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.07.049

Spatially Driven DNA-Based Probe Proximity Assay for Total Antibody Quantification in Antibody-Drug Conjugates

Chen, Z., Liao, Y., Zhou, Y., Zhang, Z., Huang, J., Zhao, Z., Zhu, S., Crommen, J., Wang, Q., & Jiang, Z. (2026) · ACS Sensors · doi:10.1021/acssensors.6c01759

Comparative safety profiles of antibody-drug conjugates: a real-world analysis of monotherapy and combination regimens in solid tumors

Fan, L., Yin, Y., Zhuang, W., He, D., Wan, R., Sun, B., Bai, H., & Wang, J. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2712694

Activatable photoimmunotherapy enables spatiotemporal depletion of pathogenic cells in immune-driven disease and cancer

Kercher, E. M., Sadiki, A., Liu, S., Essien, K. I., Scudiere, J., Finlay, W. J. J., Epperly, A. H., Zhou, Z. S., Spring, B. Q., & Harris, J. E. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.07.025

Deubiquitinase-targeting chimeras (DUBTACs): a game-changing approach for targeted protein stabilization in drug discovery

Hailu, G. S., Fabbrizi, E., Mancini, A., Fiorentino, F., Mai, A., & Rotili, D. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104769

From probe to prodrug: immunoproteasome activity as a trigger for disease-selective therapeutics

Loy, C. A., Gu, Y., Kim, S., Mohagheghi, M. V., Trask, N. B., Suarez-Pizarro, M., Wagar, L. E., Benavente, C. A., & Trader, D. J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02835-w

Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan

Wang, J., Jiang, H., Niu, J., Liu, L., Wu, Y., Shi, J., Liu, L., Yin, S., Feng, C., Zhang, L., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1907324

Pharmacokinetic modeling frameworks for complex antibody-drug conjugates analytes: clinical pharmacology considerations

Kumar, D., Verma, A., & Trivedi, N. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118364

Mechanisms of resistance to antibody-drug conjugates in bladder cancer

Liu, K., Xu, F., Wu, C., & Wang, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1882868

Exploring the landscape of targetable alterations in patients with glioblastoma

Aquilanti, E., Touat, M., French, P. J., Iavarone, A., Capper, D., Geurts, M., Rahman, R. M., Verhaak, R. G. W., Preusser, M., van den Bent, M. J., et al. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01190-7

Antibody–drug conjugate development in lymphoma: a systematic clinical trial landscape analysis

Zhang, H., Li, J., Yan, H., & Liu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1855476

Antibody-Mediated Therapies in Urothelial Carcinoma: A Critical Narrative Review

Go, S., Xavier, V. F. D. C., Kang, M. H., & Lee, W. S. (2026) · Cancers · doi:10.3390/cancers18172743

An evaluation of becotatug vedotin for the treatment of recurrent or metastatic nasopharyngeal cancer

Wang, X., & Han, F. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2721409

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

Wang, J., Romaniuk, R., & Svilenov, H. L. (2026) · FEBS Letters · doi:10.1002/1873-3468.70430

Antibody–Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges

Paliogiannis, P., Fara, G., Zinellu, A., Fois, A. G., & Palmieri, G. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48090868

Drug conjugates for anticancer drug delivery

Marwaha, D., Gupta, P., Singh, N., Gupta, A., & Sharma, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44185-1.00023-9

Next Generation Antibody–Drug Conjugates: Molecular Design Innovations And Overcoming Resistance – A Comprehensive Review

Hari Nandhini.A, D. S. S. M. B. R. (2025) · Vascular and Endovascular Review · doi:10.64149/j.ver.8.16s.217-224

Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs

Metrangolo, V., & Engelholm, L. H. (2024) · Cancers · doi:10.3390/cancers16020447 · Cited by 77

Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs

Wu, D., Yang, K., He, R., Yin, R., & Shui, L. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1669592 · Cited by 25

Antibody-drug conjugates: mechanism, progress and future directions of cancer targeted therapy

Li, M., Wu, G., Chen, B., Zheng, Z., Ning, X., Li, J., De, Z., Li, J., & Song, J. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02817-0

Unlocking the potential of antibody–drug conjugates for cancer therapy

Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,209